Eli Lilly and Company (BCBA:LLYD)
Argentina · Delayed Price · Currency is ARS · Price in USD | Market Cap | 1,573.76T +78.9% |
| Revenue (ttm) | 99.81T +47.4% |
| Net Income | 34.92T +127.6% |
| EPS | 38,891.17 +129.1% |
| Shares Out | n/a |
| PE Ratio | 45.07 |
| Forward PE | 33.41 |
| Dividend | 107.54 (0.33%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 898 |
| Open | 22.39 |
| Previous Close | 21.98 |
| Day's Range | 22.15 - 22.99 |
| 52-Week Range | 11.20 - 23.19 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements
The two companies dominate the market for obesity medications.
As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize
The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.
Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads
Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry bet...
Lilly's Next-Generation Obesity Shot Clears Another Hurdle
Eli Lilly & Co.'s next-generation weight-loss shot retatrutide didn't increase overall heart risk in a new study, helping dispel concerns over its potential. The company plans to file for US Food and ...
Eli Lilly (LLY) Targets 2027 for Approval of Its Next-Generation Obesity Drug
The new medication helps people who also have diabetes and cardiovascular disease.
Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds
Analysts have suggested retatrutide could become a blockbuster weight loss drug if approved. In January, TD Cowen analysts estimated retatrutide could generate $3.8 billion in sales in 2030, while Glo...
Eli Lilly notes retatrutide met primary endpoint in TRIUMPH-2, TRIUMPH-3 trials
Eli Lilly (LLY) announced topline results from TRIUMPH-2 and TRIUMPH-3, two Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor a...
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
Eli Lilly on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administration ...
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials. The drug delivered significant w...
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults ...
Weight loss drugs linked to increase risk of hair loss
Weight loss drugs such as Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers.
Hair loss with GLP-1 drugs is rare, but real, studies find
The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that ...
Many US patients opt for obesity drug injections, defying some expectations
Many patients have opted for injectable forms of the wildly popular GLP-1 obesity medications through a pilot program of the U.S. government's Medicare health insurance program for Americans aged 65 ...
Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later
President Donald Trump said on Tuesday all generic drugs being brought into the U.S. will continue having a tariff of 0% for two years starting from August 1, after which the tariff rate wi...
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.
Lilly tells Bloomberg ads ‘truthful,’ will defend against Novo suit ‘vigorously’
A spokesperson for Eli Lilly (LLY) told Bloomberg that the company’s weight loss drug ads are “truthful” and “transparent,” adding that the company will defend itself “vigorously” against the lawsuit…
Novo Sues Rival Lilly Over Weight-Loss Ads
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo'...
Eli Lilly (LLY) Hit with Lawsuit by Rival Novo Nordisk Over Weight-Loss Drug Ads
Competition between the drug makers is intensifying.
Cramer's Mad Dash: Eli Lilly
CNBC's Jim Cramer delivers his daily Mad Dash.
Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ...
Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims
Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss dr...
Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs